PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone HR1/HER2-early breast cancer

被引：0
|
作者：
Mayer, E. L. [1 ]
Demichele, A. M. [2 ]
Pfeiler, G. [3 ]
Barry, W. [4 ]
Metzger, O. [5 ]
Rastogi, P. [6 ]
Symmans, F. [7 ]
Burstein, H. J. [4 ]
Miller, K. [8 ]
Loibl, S. [9 ]
Schmatloch, S. [10 ]
Goulioti, T. [11 ]
Zardavas, D. [11 ]
Fesl, C. [12 ]
Koehler, M. [13 ]
Bartlett, C. Huang [13 ]
Huang, X. [14 ]
Piccart, M. [15 ]
Winer, E. [4 ]
Gnant, M. [16 ,17 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA USA
[2] Univ Penn, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA
[3] Med Univ Vienna, Gyneol & Obstet, Vienna, Austria
[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[5] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[6] Univ Pittsburgh Sch Hlth Sci, Div Hematol Oncol, Pittsburgh, PA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[8] Indiana Univ Sch Med, Hematol Oncol, Indianapolis, IN 46202 USA
[9] German Breast Grp GBG Forsch GmbH, Med & Res, Neu Isenburg, Germany
[10] Elisabeth Hosp, Senol, Kassel, Germany
[11] Breast Int Grp, Brussels, Belgium
[12] Austrian Breast & Colorectal Canc Study Grp ABCSG, Stat, Vienna, Austria
[13] Pfizer, Oncol, New York, NY USA
[14] Pfizer, Oncol, San Diego, CA USA
[15] Inst Jules Bordet, Chemotherapy Dept, Brussels, Belgium
[16] Med Univ Vienna, Dept Surg, Vienna, Austria
[17] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2-early breast cancer: Primary results from the phase III NATALEE trial.
    Stroyakovskiy, Daniil J.
    Yardley, Denise A.
    Huang, Chiun-Sheng
    Fasching, Peter A.
    Crown, John
    Bardia, Aditya
    Chia, Stephen
    Im, Seock-Ah
    Martin, Miguel
    Loi, Sherene
    Xu, Binghe
    Hurvitz, Sara A.
    Barrios, Carlos
    Untch, Michael
    Moroose, Rebecca L.
    Visco, Fran
    Fresco, Rodrigo
    Taran, Tetiana
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA500 - LBA500
  • [22] A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2-early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
    Hamilton, Erika
    Loibl, Sibylle
    Niikura, Naoki
    Rastogi, Priya
    Saini, Kamal S.
    Gioni, Ioanna
    Klinowska, Teresa
    Mayer, Ingrid A.
    Stuart, Mary
    Syta, Emilia
    Walding, Andrew
    Bachelot, Thomas
    CANCER RESEARCH, 2024, 84 (09)
  • [23] Phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor-positive/HER2-negative resected isolated locoregional recurrence of breast cancer - The POLAR Trial
    Munzone, Elisabetta
    Aebi, Stefan
    Janez, Noelia Martinez
    Guth, Uwe
    Bellet, Meritxell
    Pistilli, Barbara
    Balic, Marija
    Roschitzki-Voser, Heidi
    Regan, Meredith M.
    CANCER RESEARCH, 2021, 81 (04)
  • [24] The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early + /HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials
    Keskinkilic, Merve
    Arayici, Mehmet Emin
    Basbinar, Yasemin
    Ellidokuz, Hulya
    Yavuzsen, Tugba
    Oztop, Ilhan
    BREAST, 2024, 78
  • [25] Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2-breast cancer (ABCSG-42/AFT-05/BIG-14-13)
    Metzger, Otto
    Ballman, Karla V.
    Gnant, Michael
    Watson, Mark
    Chen, Eveline
    Tran, Kevin
    O'Brien, Patrick
    Hlauschek, Dominik
    Martin, Miguel
    Balko, Justin M.
    Nowecki, Zbigniew
    Hahn, Olwen Mary
    Denkert, Carsten
    Curtis, Christina
    Liu, Yuan
    Dueck, Amylou C.
    Fesl, Christian
    Mayer, Erica L.
    DeMichele, Angela
    Symmans, W. Fraser Fraser
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma
    Mayer, E. L.
    DeMichele, A.
    Rugo, H. S.
    Miller, K.
    Waks, A. G.
    Come, S. E.
    Mulvey, T.
    Jeselsohn, R.
    Overmoyer, B.
    Guo, H.
    Barry, W. T.
    Bartlett, C. Huang
    Koehler, M.
    Winer, E. P.
    Burstein, H. J.
    ANNALS OF ONCOLOGY, 2019, 30 (09) : 1514 - 1520
  • [27] Examining the association between patient-reported outcomes and physical activity metrics in patients with HR1/ HER2 advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone
    Oba, Mari S.
    Miyaji, Tempei
    Bando, Hiroko
    Ueda, Aya
    Terada, Kaori
    Doi, Mihoko
    Nagai, Shigenori
    Hattori, Masaya
    Watanabe, Kenichi
    Tamura, Nobuko
    Niikura, Naoki
    Muramatsu, Yasuaki
    Xu, Linghua
    Matsui, Asuka
    Masuda, Norikazu
    Saji, Shigehira
    QUALITY OF LIFE RESEARCH, 2024, 33 : S40 - S41
  • [28] ADAPTcycle - adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2-early breast cancer
    Harbeck, N.
    Gluz, O.
    Christgen, M.
    Graeser, M.
    Hilpert, F.
    Kreipe, H. H.
    Nitz, U.
    Kates, R.
    Schinkoethe, T.
    Kuemmel, S.
    BREAST, 2019, 44 : S133 - S133
  • [29] Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
    Mayer, Erica L.
    Fesl, Christian
    Hlauschek, Dominik
    Garcia-Estevez, Laura
    Burstein, Harold J.
    Zdenkowski, Nicholas
    Wette, Viktor
    Miller, Kathy D.
    Balic, Marija
    Mayer, Ingrid A.
    Cameron, David
    Winer, Eric P.
    Lorenzo, Jose Juan Ponce
    Lake, Diana
    Pristauz-Telsnigg, Gunda
    Haddad, Tufia C.
    Shepherd, Lois
    Iwata, Hiroji
    Goetz, Matthew
    Cardoso, Fatima
    Traina, Tiffany A.
    Sabanathan, Dhanusha
    Breitenstein, Urs
    Ackerl, Kerstin
    Metzger Filho, Otto
    Zehetner, Karin
    Solomon, Kadine
    El-Abed, Sarra
    Theall, Kathy Puyana
    Lu, Dongrui Ray
    Dueck, Amylou
    Gnant, Michael
    DeMichele, Angela
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) : 449 - +
  • [30] Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2-Breast Cancer
    Bottosso, Michele
    Miglietta, Federica
    Vernaci, Grazia Maria
    Giarratano, Tommaso
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Griguolo, Gaia
    CLINICAL CANCER RESEARCH, 2024, 30 (14) : 2884 - 2894
12345